 Connection
Maria Amaya to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications Maria Amaya has written about Hematopoietic Stem Cell Transplantation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.333 |
|
|
|
-
Kent A, Gil KB, Jones MK, Linden B, Purev E, Haverkos B, Schwartz M, McMahon C, Amaya M, Smith CA, Bosma G, Abbott D, Rabinovitch R, Milgrom SA, Pollyea DA, Gutman JA. Outcomes of Haplo-Cord Versus Dual Cord Transplants: A Single-Center Retrospective Analysis. Transplant Cell Ther. 2025 Apr; 31(4):267.e1-267.e11.
Score: 0.155
-
Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 08; 58(8):849-854.
Score: 0.141
-
Fang J, Bosma G, Aisner D, McMahon C, Amaya M, Schwartz M, Kaiser J, Abbott D, Pan Z, Schowinsky J, Pang C, Gutman JA, Pollyea DA. White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia. Leuk Lymphoma. 2024 Jun; 65(6):800-807.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|